cagrisema vs tirzepatide
updated
cagrisema (tier B) vs tirzepatide (tier S): what each is, half-life and source counts side by side.
cagrisema · tier B
semaglutide + cagrilintide. first fixed-dose GLP-1 + amylin combo. FDA review underway 2026.
tier rationale
B-tier because the drug is not FDA-approved yet. clinical evidence is drug-grade: phase-3 program across 4,600 patients, NEJM, NDA filed. S is reserved for compounds with a decision issued. on FDA approval (expected late 2026) this moves to S. could also move up if REDEFINE-11 or higher-dose escalation finally hits the 25% novo originally targeted.
tirzepatide · tier S
A dual GIP and GLP-1 receptor agonist with distinct Zepbound and Mounjaro labels.
tier rationale
Tirzepatide is in S tier because large randomized trials have shown weight loss, improved blood-sugar control and reduced sleep-apnea severity. Zepbound and Mounjaro have US approvals for these uses.
at a glance
| cagrisema | tirzepatide | |
|---|---|---|
| tier | B | S |
| category | weight loss | weight loss |
| sources | 28 | 20 |
| claims evaluated | 7 | n/a |
| half-life | ~168 hours | ~5 days |
| dosing data | yes | yes |
reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.